Open AccessPharmacological Properties of BN82451: A Novel Multitargeting Neuroprotective Agent
Author(s) -
Chabrier Pierre Etienne,
Auguet Michel
Publication year - 2007
Publication title -
cns drug reviews
Language(s) - English
Resource type - Journals
eISSN - 1527-3458
pISSN - 1080-563X
DOI - 10.1111/j.1527-3458.2007.00018.x
Subject(s) - neuroprotection , pharmacology , amyotrophic lateral sclerosis , in vivo , neuroscience , central nervous system , ischemia , medicine , chemistry , biology , disease , pathology , microbiology and biotechnology
BN82451 belongs to a new family of small molecules designated as multitargeting or hybrid molecules. BN82451 is orally active, has good central nervous system penetration, and elicits potent neuronal protection and antiinflammatory properties. Neuronal protection is due to Na + channel blockade, antioxidant properties, and mitochondria‐protecting activity, whereas inhibition of cyclooxygenases is mostly responsible for its antiinflammatory activity. BN82451 has been shown to exert a potent neuroprotective effect in various in vitro and in vivo animal models. BN82451 was found to exert a significant protection in experimental animal models mimicking aspects of cerebral ischemia, Parkinson disease, Huntington disease, and more particularly amyotrophic lateral sclerosis. Collectively, its pharmacological properties designate BN82451 as a promising neuroprotective agent.